Results 11 to 20 of about 57,349 (269)

Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles

International Journal of Nanomedicine, 2014
Alicia Rodríguez-Gascón, Ana del Pozo-Rodríguez, María Ángeles SolinísPharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray ...
Rodríguez-Gascón A, del Pozo-Rodríguez A, Solinís MA   +2 more
doaj   +8 more sources

Progress in researches on self-amplifying RNA vaccines

Zhongguo gonggong weisheng, 2023
Self-amplifying RNA (saRNA) vaccines are a new generation of mRNA vaccines. In addition to containing mRNA sequences encoding antigen proteins, saRNA vaccines also have unique self-amplifying elements, so self-amplification of antigen sequences can be ...
Shuo WANG, Jianmin LI
doaj   +2 more sources

Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA [PDF]

Molecular Therapy, 2021
Self-amplifying RNA (saRNA) is a cutting-edge platform for both nucleic acid vaccines and therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which enhances the immunogenicity of RNA vaccines but can also lead to inhibition of translation.
Anna K. Blakney, Paul F. McKay, Clément R. Bouton, Kai Hu, Karnyart Samnuan, Robin J. Shattock   +5 more
openaire   +6 more sources

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. [PDF]

J Control Release, 2021
Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from degradation. To date, delivery platforms for saRNA have included lipid nanoparticles (LNP), polyplexes and cationic nanoemulsions; of these LNP are the most clinically advanced ...
Blakney AK, McKay PF, Hu K, Samnuan K, Jain N, Brown A, Thomas A, Rogers P, Polra K, Sallah H, Yeow J, Zhu Y, Stevens MM, Geall A, Shattock RJ.   +14 more
europepmc   +7 more sources

Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids [PDF]

Molecular Therapy: Nucleic Acids, 2018
Advances in RNA technology during the past two decades have led to the construction of replication-competent RNA, termed replicons, RepRNA, or self-amplifying mRNA, with high potential for vaccine applications.
Pavlos C. Englezou, Cedric Sapet, Thomas Démoulins, Panagiota Milona, Thomas Ebensen, Kai Schulze, Carlos-Alberto Guzman, Florent Poulhes, Olivier Zelphati, Nicolas Ruggli, Kenneth C. McCullough   +10 more
doaj   +4 more sources

Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles [PDF]

Vaccines, 2014
Dendritic cells (DC) play essential roles determining efficacy of vaccine delivery with respect to immune defence development and regulation. This renders DCs important targets for vaccine delivery, particularly RNA vaccines.
Kenneth C. McCullough, Panagiota Milona, Lisa Thomann-Harwood, Thomas Démoulins, Pavlos Englezou, Rolf Suter, Nicolas Ruggli   +6 more
doaj   +4 more sources

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Nature Communications, 2020
Here, the authors develop a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle as a vaccine candidate and show induction of neutralization antibody titers in mice that are comparable to titers in ...
Paul F. McKay, Kai Hu, Anna K. Blakney, Karnyart Samnuan, Jonathan C. Brown, Rebecca Penn, Jie Zhou, Clément R. Bouton, Paul Rogers, Krunal Polra, Paulo J. C. Lin, Christopher Barbosa, Ying K. Tam, Wendy S. Barclay, Robin J. Shattock   +14 more
doaj   +2 more sources

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines. [PDF]

PLoS Pathogens, 2022
The optimal vaccination strategy to boost responses in the context of pre-existing immune memory to the SARS-CoV-2 spike (S) glycoprotein is an important question for global public health.
Tamara Elliott, Hannah M Cheeseman, Abbey B Evans, Suzanne Day, Leon R McFarlane, Jessica O'Hara, Mohini Kalyan, Fahimah Amini, Tom Cole, Alan Winston, Sarah Fidler, Katrina M Pollock, James A Harker, Robin J Shattock   +13 more
doaj   +2 more sources

The advent of clinical self-amplifying RNA vaccines

Molecular Therapy
Self-amplifying RNA (saRNA) technology is an emerging platform for vaccine development, offering significant advantages over conventional mRNA vaccines. By enabling intracellular amplification of RNA, saRNA facilitates robust antigen expression at lower doses, thereby enhancing both immunogenicity and cost-effectiveness. This review examines the latest
Irafasha C. Casmil, Jongwoo Jin, Eun-Jeong Won, Cynthia Huang, Suiyang Liao, Hyunjoo Cha-Molstad, Anna K. Blakney   +6 more
openaire   +4 more sources

Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis [PDF]

Nature Communications, 2020
Antimicrobial peptide LL37 can bind nucleic acids and potentiate their sensing by endosomal TLRs. Here the authors show that LL37 binds to RNA from neutrophil extracellular traps (NETs), which amplifies inflammation and production of more LL37 and NETs ...
Franziska Herster, Zsofia Bittner, Nathan K. Archer, Sabine Dickhöfer, David Eisel, Tatjana Eigenbrod, Thomas Knorpp, Nicole Schneiderhan-Marra, Markus W. Löffler, Hubert Kalbacher, Tim Vierbuchen, Holger Heine, Lloyd S. Miller, Dominik Hartl, Lukas Freund, Knut Schäkel, Martin Heister, Kamran Ghoreschi, Alexander N. R. Weber   +18 more
doaj   +3 more sources